

**Supplementary Table 2.** The number of intravitreal anti-VEGF injection including aflibercept and ranibizumab in newly diagnosed exudative AMD; injections for 1 year after diagnosis of disease, for 2 years after diagnosis of disease, and for 3 years after diagnosis of disease

	Total			Ranibizumab			Aflibercept		
	New patients on treatment/total new patients	Injections during the first year	Mean number of injections	New patients on treatment/total new patients	Injections during the first year	Mean number of injections	New patients on treatment/total new patients	Injections during the first year	Mean number of injections
<b>1 year after diagnosis</b>									
2010	4,249/6,591 (64.5)	14,741	3.47 (1-12)	4,249/6,591 (64.5)	14,741	3.47 (1-12)			
2011	4,398/6,299 (69.8)	15,373	3.50 (1-11)	4,308/6,299 (69.8)	15,373	3.50 (1-11)			
2012	4,259/6,202 (68.7)	15,916	3.74 (1-11)	4,259/6,202 (68.7)	15,916	3.74 (1-11)			
2013	4,589/6,600 (69.5)	17,594	3.83 (1-12)	4,568/6,600 (69.2)	17,522	3.84 (1-11)	40/6,600 (0.6)	72	1.80 (1-4)
2014	5,059/7,124 (71.0)	20,650	4.08 (1-14)	3,295/7,124 (46.3)	12,486	3.79 (1-14)	2,228/7,124 (31.3)	8,164	3.66 (1-10)
2015	6,656/10,029 (66.4)	27,882	4.19 (1-14)	3,739/10,029 (37.3)	14,496	3.88 (1-14)	3,674/10,029 (36.6)	13,386	3.64 (1-12)
2016	7,148/11,064 (64.6)	30,331	4.24 (1-14)	3,276/11,064 (29.6)	12,625	3.85 (1-11)	4,632/11,064 (41.9)	17,706	3.82 (1-13)
2017	7,800/11,866 (65.7)	31,749	4.07 (1-18)	2,912/11,866 (24.5)	10,737	3.69 (1-15)	5,601/11,866 (47.2)	21,012	3.75 (1-12)
2018	8,491/12,896 (65.8)	34,451	4.06 (1-17)	3,249/12,896 (25.2)	12,297	3.78 (1-17)	5,982/12,896 (46.4)	22,154	3.70 (1-13)
Total	52,646/78,671 (66.9)	208,687	3.96 (1-18)	33,942/78,671 (43.1)	126,193	2.95 (1-16)	22,157/78,671 (28.2)	82,494	3.72 (1-13)
<b>2 year after diagnosis</b>									
2010	4,306/6,591 (65.3)	15,815	3.67 (1-12)	4,306/6,591 (65.3)	15,815	3.67 (1-12)			
2011	4,459/6,299 (70.8)	17,374	3.90 (1-15)	4,459/6,299 (70.8)	17,374	3.90 (1-15)			
2012	4,339/6,202 (70.0)	18,997	4.38 (1-13)	4,324/6,202 (69.7)	18,949	4.38 (1-13)	29/6,202 (0.5)	48	1.66 (1-4)
2013	4,738/6,600 (71.8)	22,744	4.80 (1-14)	4,633/6,600 (70.2)	21,178	4.57 (1-14)	590/6,600 (8.9)	1,566	2.65 (1-9)
2014	5,185/7,124 (72.8)	27,361	5.28 (1-15)	3,414/7,124 (47.9)	15,383	4.51 (1-15)	2,597/7,124 (36.5)	11,978	4.61 (1-15)
2015	6,800/10,029 (67.8)	36,958	5.44 (1-15)	3,839/10,029 (38.3)	17,610	4.59 (1-15)	4,097/10,029 (40.9)	19,348	4.72 (1-14)
2016	7,340/11,064 (66.3)	40,940	5.58 (1-22)	3,440/11,064 (31.1)	15,835	4.60 (1-22)	5,023/11,064 (45.4)	25,105	5.00 (1-22)
2017	8,022/11,866 (67.6)	43,990	5.48 (1-25)	3,124/11,866 (26.3)	14,142	4.53 (1-25)	5,955/11,866 (50.2)	29,848	5.01 (1-23)
Total	45,189/65,775 (68.7)	224,179	4.96 (1-25)	31,539/65,775 (47.9)	136,286	4.32 (1-25)	18,291/65,775 (27.8)	87,893	4.81 (1-23)

Supplementary Table 2. Continued

	Total			Ranibizumab			Aflibercept		
	New patients on treatment/total new patients	Injections during the first year	Mean number of injections	New patients on treatment/total new patients	Injections during the first year	Mean number of injections	New patients on treatment/total new patients	Injections during the first year	Mean number of injections
3 year after diagnosis									
2010	4,352/6,591 (66.0)	17,097	3.93 (1-13)	4,352/6,591 (66.0)	17,097	3.93 (1-13)			
2011	4,507/6,299 (71.6)	19,288	4.28 (1-15)	4,496/6,299 (71.4)	19,251	4.28 (1-15)	21/6,299 (0.3)	37	1.76 (1-4)
2012	4,412/6,202 (71.1)	22,003	4.99 (1-16)	4,358/6,202 (70.3)	20,975	4.81 (1-16)	409/6,202 (6.6)	1,028	2.51 (1-9)
2013	4,805/6,600 (72.8)	26,670	5.55 (1-15)	4,670/6,600 (70.8)	23,285	4.99 (1-14)	897/6,600 (13.6)	3,385	3.77 (1-14)
2014	5,261/7,124 (73.8)	31,792	6.04 (1-17)	3,452/7,124 (48.5)	16,780	4.86 (1-17)	2,792/7,124 (39.2)	15,012	5.38 (1-16)
2015	6,904/10,029 (68.8)	43,878	6.36 (1-25)	3,909/10,029 (39.0)	19,441	4.97 (1-21)	4,345/10,029 (43.3)	24,437	5.62 (1-20)
2016	7,505/11,064 (67.8)	50,435	6.72 (1-34)	3,565/11,064 (32.2)	18,274	5.13 (1-34)	5,304/11,064 (47.9)	32,161	6.06 (1-33)
Total	37,746/53,909 (70.0)	211,163	5.59 (1-34)	28,802/53,909 (47.9)	135,103	4.69 (1-34)	18,291/65,775 (27.8)	76,060	5.52 (1-33)

Values are presented as number (% or range).

VEGF = vascular endothelial growth factor; AMD = age-related macular degeneration.